Please use this identifier to cite or link to this item:
http://hdl.handle.net/20.500.12188/28302| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Milenkovikj, Tatjana | en_US |
| dc.contributor.author | Jovanovska Mishevska, Sasha | en_US |
| dc.contributor.author | Bitoska Mileva, Iskra | en_US |
| dc.contributor.author | Ahmeti, Irfan | en_US |
| dc.contributor.author | Chekorova Mitreva, Biljana | en_US |
| dc.date.accessioned | 2023-10-24T07:20:07Z | - |
| dc.date.available | 2023-10-24T07:20:07Z | - |
| dc.date.issued | 2023-04 | - |
| dc.identifier.uri | http://hdl.handle.net/20.500.12188/28302 | - |
| dc.description.abstract | Safety and efficacy of once weekly (OW) subcutaneous (s.c.) semaglutide in T2D patients has been established in phase 3 clinical trials. In North Macedonia, no real-world evidence studies were conducted so far to assess the use of once weekly (OW) semaglutide in routine clinical practice. | en_US |
| dc.language.iso | en | en_US |
| dc.title | Once-weekly subcutaneous semaglutide use I GLP-1 naïve patients with type 2 diabetes in North Macedonia: real world data from the MIRAGE study. | en_US |
| dc.type | Proceeding article | en_US |
| dc.relation.conference | Congress of the Central European Diabetes Association (CEDA) | en_US |
| item.grantfulltext | open | - |
| item.fulltext | With Fulltext | - |
| crisitem.author.dept | Faculty of Medicine | - |
| crisitem.author.dept | Faculty of Medicine | - |
| crisitem.author.dept | Faculty of Medicine | - |
| crisitem.author.dept | Faculty of Medicine | - |
| Appears in Collections: | Faculty of Medicine: Conference papers | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| OP 2 Abstracts_engl_CEDA_congress_2023.pdf | 1.82 MB | Adobe PDF | View/Open |
Page view(s)
48
checked on Sep 22, 2024
Download(s)
154
checked on Sep 22, 2024
Google ScholarTM
Check
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.